Cargando…

Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis

BACKGROUND: Mild to moderate adverse events (AEs) are common after treatment of lymphatic filariasis (LF) and pose a major challenge for the global LF elimination program. We studied changes in cytokine levels and filarial worm components in plasma of subjects with and without AEs following treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersen, Britt J, Kumar, Jessica, Curtis, Kurt, Sanuku, Nelly, Satofan, Samson, King, Christopher L, Fischer, Peter U, Weil, Gary J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853815/ https://www.ncbi.nlm.nih.gov/pubmed/29149303 http://dx.doi.org/10.1093/infdis/jix578

Ejemplares similares

A Randomized Trial of a New Triple Drug Treatment for Lymphatic Filariasis
por: King, Christopher L., et al.
Publicado: (2018)

IgG(4) antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis
por: Greene, Sarah E., et al.
Publicado: (2023)

Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis
por: Andersen, Britt J., et al.
Publicado: (2019)

Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
por: Budge, Philip J., et al.
Publicado: (2018)

Development and Introduction of the Filariasis Test Strip: A New Diagnostic Test for the Global Program to Eliminate Lymphatic Filariasis
por: Pantelias, Anastasia, et al.
Publicado: (2022)

A comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia with low-level persistence of lymphatic filariasis following mass drug administration
por: Yahathugoda, Thishan C., et al.
Publicado: (2015)

Geospatial modelling of lymphatic filariasis and malaria co-endemicity in Nigeria
por: Eneanya, Obiora A, et al.
Publicado: (2023)

Combining different diagnostic studies of lymphatic filariasis for risk mapping in Papua New Guinea: a predictive model from microfilaraemia and antigenaemia prevalence surveys
por: Berg Soto, Alvaro, et al.
Publicado: (2018)

Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease
por: Ramaiah, K. D., et al.
Publicado: (2014)

Filarial Antigenemia and Loa loa Night Blood Microfilaremia in an Area Without Bancroftian Filariasis in the Democratic Republic of Congo
por: Bakajika, Didier K., et al.
Publicado: (2014)

Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali
por: Dolo, Housseini, et al.
Publicado: (2020)

A Review of Factors That Influence Individual Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis
por: Krentel, Alison, et al.
Publicado: (2013)

Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis – a multicenter trial
por: Lammie, Patrick J, et al.
Publicado: (2004)

Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis
por: Turner, Hugo C., et al.
Publicado: (2017)

Identification and characterization of Loa loa antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic filariasis
por: Hertz, Marla I., et al.
Publicado: (2018)

A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery
por: Weil, Gary J, et al.
Publicado: (2020)

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa
por: Fischer, Peter U., et al.
Publicado: (2017)

A case study of risk factors for lymphatic filariasis in the Republic of Congo
por: Chesnais, Cédric B, et al.
Publicado: (2014)

Recombinant antigens used as diagnostic tools for lymphatic filariasis
por: Pastor, André Filipe, et al.
Publicado: (2021)

Modeling the Impact and Costs of Semiannual Mass Drug Administration for Accelerated Elimination of Lymphatic Filariasis
por: Stolk, Wilma A., et al.
Publicado: (2013)

Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial
por: Bjerum, Catherine M, et al.
Publicado: (2019)

MDA—Lymphatic Filariasis
por: Ichimori, Kazuyo
Publicado: (2014)

Urban lymphatic filariasis
por: Simonsen, Paul E., et al.
Publicado: (2012)

The Diagnosis of Lymphatic Obstruction of Filarial Origin
por: Acton, Hugh W., et al.
Publicado: (1931)

The filarial and the antibiotics: Single or combination therapy using antibiotics for filariasis
por: Fordjour, Fatima Amponsah, et al.
Publicado: (2022)

Adjuvant-free immunization with infective filarial larvae as lymphatic homing antigen carriers
por: Card, Catherine, et al.
Publicado: (2020)

Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo
por: Chesnais, Cédric B., et al.
Publicado: (2019)

Endpoints for Lymphatic Filariasis Programs
por: Grady, Caroline A., et al.
Publicado: (2007)

Mapping of lymphatic filariasis in Nepal
por: Sherchand, Jeevan B, et al.
Publicado: (2003)

Elimination of Lymphatic Filariasis in The Gambia
por: Rebollo, Maria P., et al.
Publicado: (2015)

Portable infrared imaging for longitudinal limb volume monitoring in patients with lymphatic filariasis
por: Zhou, Celia, et al.
Publicado: (2019)

Rapid progress towards elimination of lymphatic filariasis in endemic regions of Myanmar as a result of 16 years of anti-filarial activities (2001–2016)
por: Win, Kyawt Mon, et al.
Publicado: (2018)

Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic Filariasis Prevalence in Flores Island, Indonesia
por: Supali, Taniawati, et al.
Publicado: (2019)

Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis
por: Weil, Gary J., et al.
Publicado: (2022)

Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach
por: Goss, Charles W., et al.
Publicado: (2019)

Comparison of Immunochromatographic Test (ICT) and Filariasis Test Strip (FTS) for Detecting Lymphatic Filariasis Antigen in American Samoa, 2016
por: Sheel, Meru, et al.
Publicado: (2021)

Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d’Ivoire: A randomized controlled superiority study
por: Bjerum, Catherine M., et al.
Publicado: (2023)

Diagnostics to support elimination of lymphatic filariasis—Development of two target product profiles
por: Won, Kimberly Y., et al.
Publicado: (2021)

The history of the elimination of lymphatic filariasis in China
por: De-jian, Sun, et al.
Publicado: (2013)

Lymphatic Filariasis Disseminating to the Upper Extremity
por: Maldjian, Catherine, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_obamhbj2kii96tk5165h6535m6